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Abstract
To follow the fate of CD8+ T cells responsive to Plasmodium berghei ANKA (PbA) infection, we generated an MHC I-restricted
TCR transgenic mouse line against this pathogen. T cells from this line, termed PbT-I T cells, were able to respond to blood-
stage infection by PbA and two other rodent malaria species, P. yoelii XNL and P. chabaudi AS. These PbT-I T cells were also
able to respond to sporozoites and to protect mice from liver-stage infection. Examination of the requirements for priming
after intravenous administration of irradiated sporozoites, an effective vaccination approach, showed that the spleen rather
than the liver was the main site of priming and that responses depended on CD8a+ dendritic cells. Importantly, sequential
exposure to irradiated sporozoites followed two days later by blood-stage infection led to augmented PbT-I T cell
expansion. These findings indicate that PbT-I T cells are a highly versatile tool for studying multiple stages and species of
rodent malaria and suggest that cross-stage reactive CD8+ T cells may be utilized in liver-stage vaccine design to enable
boosting by blood-stage infections.
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Introduction
Malaria is a mosquito-transmitted disease found in a range of
animals including man, non-human primates and rodents. It is
caused by multiple Plasmodium species, several of which may infect
the same animal species. For humans, the two most prevalent
Plasmodium species are P. falciparum and P. vivax, with the former
responsible for the bulk of lethal disease. Mice have been used as a
convenient animal model for studying malaria, with three rodent
Plasmodium species in use: (i) P. chabaudi, which can cause a disease
that shows recrudescence and has many features in common with
human malaria including anemia, sequestration of parasites, and
metabolic acidosis [1]; (ii) P. yoelii, which has two very closely
related strains that differ in their capacity to infect red blood cells
and cause lethal disease [2]; and (iii) P. berghei, particularly the
ANKA strain (PbA), which has been used as a model for human
cerebral malaria [3,4,5], a lethal complication of P. falciparum
infection. While there is much debate as to the relevance of the
PbA rodent infection model to human disease, the pathological
processes underlying human cerebral malaria are relatively poorly
characterized, making it difficult to accurately compare human
and murine diseases. However, like human severe malaria, high
parasite burden is required for multi-organ pathology in the PbA
model [6,7,8]. In itself, the pathological process underlying
experimental cerebral malaria (ECM) seen in PbA infections also
offers insight into immune-mediated pathology in general,
providing a rigorous experimental approach that can be easily
manipulated to decipher various cellular and molecular contribu-
tions. In this rodent model, various cell types and cytokines have
been reported to contribute to lethal ECM, with CD8+ T cells a
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major and essential contributor [9,10,11]. Infection with PbA
leads to the activation of parasite-specific T cells that first expand
in the spleen and then migrate to the brain, where they cause
pathology [11]. Depletion of CD8+ T cells shortly before the onset
of ECM prevents disease [11], supporting a role for these cells in
the effector phase of disease pathology.
Plasmodium species have a complex life cycle with several distinct
stages: a mosquito stage, from which sporozoites emerge to enter
the mammalian hosts during a blood meal; a liver-stage where
sporozoites enter hepatocytes and eventually develop into a large
cohort of merozoites; and a blood stage, where merozoites are
released into the blood and cause cyclic infection of erythrocytes.
Disease symptoms and immune mediated pathology associated
with malaria are limited to the blood-stage of infection, with the
preceding liver stage being asymptomatic [12]. Despite this,
sporozoite infection is not immunologically silent, with evidence
that following pathogen entry via a mosquito bite, the immune
response is initiated in the skin draining lymph nodes of mice [13],
generating protective immunity that depends on CD8+ T cells and
the cytokines TNFa and IFNc [14]. Sporozoite-specific immunity
can control infection in mice [15], non-human primates [16] and
humans [17,18], preventing development of blood-stage infection
and its associated disease. As a consequence, researchers have
explored the use of live sporozoites attenuated by irradiation or
genetic engineering [19,20,21] or non-attenuated sporozoites
controlled by drug curing, as potential approaches to vaccination
[22]. Administration of irradiated cryopreserved sporozoites via
the intravenous route was shown to provide superior immunity
compared to cutaneous injection in non-human primates and mice
[19]. More recently, vaccination of humans by the intravenous
route demonstrated protection [21]. The success of the intrave-
nous route was speculated to result from the direct access of
parasites to the liver for development of immunity at this site.
However, direct examination of where immunity was generated to
this effective route of vaccination was not attempted.
During the different life-cycle stages, Plasmodium parasites adopt
distinct morphologies and as a consequence express many stage-
specific proteins, which are often the focus of immunity and
vaccine design. However, many proteins are expressed throughout
multiple stages of the life cycle [23] and in the mammalian host
may be expected to contribute to immunity across multiple stages.
While it has been suggested that blood-stage immunity may impair
responses to liver-stage antigens [24], others have shown
protection against liver-stage infection by prior blood-stage
infection and cure [25], supporting the idea that antigens
expressed at both stages may be capable of inducing protective
immunity. However, direct demonstration of this capacity was not
provided.
Here we describe the development of an MHC I-restricted, T
cell receptor (TCR) transgenic murine line specific for PbA. We
show that transgenic T cells from this line recognize an antigen
expressed in both the blood-stage and the liver-stage of infection,
demonstrating the potential for T cells with blood-stage-specificity
to protect against sporozoite infection. T cells from this line detect
a conserved antigen expressed by several rodent Plasmodium species
including P. chabaudi and P. yoelii, rendering it a highly versatile
immunological tool for dissecting CD8+ T cell immunity in
malaria.
Results
Generation of an MHC I-restricted TCR transgenic mouse
specific for PbA
An MHC I-restricted TCR transgenic mouse line specific for
blood-stage PbA (termed PbT-I) was generated using TCR genes
isolated from a Kb-restricted hybridoma termed B4 (Figure S1)
originally derived from a T cell line isolated from a B6 mouse
infected with blood-stage PbA. Analysis of spleen and lymph node
(LN) cells from PbT-I mice showed a strong skewing towards
CD8+ T cells (Figure 1A), with essentially all splenic (Figure 1B)
and lymph node (Figure S2) CD8+ T cells expressing the Va8.3
and Vb10 transgenes. The few CD4+ T cells detected in the spleen
and lymph node also expressed these transgenic receptors, though
at a lower level indicative of co-expression of endogenous
receptors. There was no reduction in spleen or lymph node
cellularity relative to wild-type mice, with CD8+ T cells
substituting for the lack of CD4+ T cells (Figure S3). Peripheral
skewing towards CD8+ T cells was reflected in the thymus, where
a large population of mature CD8+CD42 T cells with high TCR
expression was evident (Figure S4). In this case, total thymocyte
numbers were reduced to about one third of wild-type (Figure
S3), consistent with the cellularity of other TCR transgenic mice
we have generated, and likely due to efficient positive selection
[26].
PbT-I cells respond to PbA in vitro and in vivo
To determine if PbT-I cells responded to blood-stage PbA,
purified CD8+ T cells from PbT-I mice were labeled with CFSE
and then stimulated in vitro with dendritic cells and lysate from
either infected red blood cells (iRBC) of mixed stages or enriched
as schizonts (Figure S5). This showed a dose-dependent
proliferative response to both forms of antigen, though schizont
lysate was more efficient.
To test whether PbT-I cells also responded to PbA in vivo, PbT-I
cells were labeled with CFSE and adoptively transferred into B6
mice one day before infection with blood-stage PbA. Three or 5
days later, mice were killed and the spleen and blood examined for
proliferating PbT-I cells (Figure 2A, B). This revealed a vigorous
response by PbT-I cells, which entered the blood from the spleen
after day 3. The specificity of PbT-I cells for malarial antigen was
demonstrated by their lack of response to intravenous (i.v.)
infection with herpes simplex virus type I (HSV-1), an infection
Author Summary
Malaria is a disease caused by Plasmodium species, which
have a highly complex life cycle involving both liver and
blood stages of mammalian infection. To prevent disease,
one strategy has been to induce CD8+ T cells against liver-
stage parasites, usually by immunization with stage-
specific antigens. Here we describe a T cell receptor
specificity that recognizes an antigen expressed in both
the liver and blood stages of several rodent Plasmodium
species. We generated a T cell receptor transgenic mouse
with this specificity and showed that T cells from this line
could protect against liver-stage infection. We used this
novel tool to identify the site and cell-type involved in
priming to a recently developed intravenous attenuated
sporozoite vaccine shown to have efficacy in humans. We
showed that CD8+ T cells with this specificity could protect
against liver-stage infection while causing pathology to
the blood stage. Finally, we provided evidence that T cells
with cross-stage specificity can be primed and boosted on
alternative stages, raising the possibility that antigens
expressed in multiple stages might be ideal vaccine
candidates for generating strong immunity to liver-stage
parasites.
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that efficiently stimulated viral glycoprotein B-specific transgenic T
cells (gBT-I cells) in the same mice (Figure S6).
To more precisely determine where PbT-I cells were
activated during the primary response to blood-stage PbA
infection, B6 mice were injected with CFSE-labeled PbT-I cells
one day before i.v. infection with blood-stage PbA, then
various tissues were harvested 2 days later to examine
expression of the early activation marker CD69 on PbT-I cells
(Figure 2C, D). This showed that blood-stage infection
caused T cell activation in the spleen, although some CD69
up-regulation was observed in liver-draining lymph nodes
(portal and celiac LNs). Other lymph nodes showed no
evidence of T cell activation.
To test whether PbT-I cells induced by blood-stage infection
made cytokines and were able to degranulate, as required for lytic
activity, mice were adoptively transferred with small numbers of
GFP-expressing PbT-I cells and infected i.v. with blood-stage PbA.
On day 8 post-infection, PbT-I cells were recovered from the
spleen and briefly restimulated with anti-CD3 mAb to test for
production of IFNc, TNFa and CD107a, the latter of which is a
surrogate marker for degranulation (Figure S7). This revealed
that most PbT-I cells were able to produce both cytokines and
degranulate.
PbT-I cells cause experimental cerebral malaria
As CD8+ T cells have been implicated in the pathology of
ECM, we asked whether transfer of PbT-I cells into B6 mice could
accelerate this disease. B6 mice were injected with a high (26106)
or low (26104) number of PbT-I cells or a high number of a herpes
simplex virus-specific gBT-I cells, then infected with blood-stage
PbA and monitored for disease (Figure 3A). This showed that
PbT-I cells significantly accelerated disease onset, though only by
about one day. ECM was accompanied by infiltration of PbT-I
cells and endogenous CD8+ T cells, but not gBT-I cells into the
brain of infected mice on days 5–6 post-infection (Figure 3B and
Figure S8).
To determine whether PbT-I cells could themselves cause
ECM, endogenous CD8+ T cells were depleted from mice with
anti-CD8 mAb and 7 days later replaced with PbT-I cells, control
gBT-I cells or no T cells. One day later, these mice were infected
with blood-stage PbA and examined for ECM onset. All mice
given PbT-I cells developed ECM, while very few other CD8-
depleted mice developed disease (Figure 4). Onset of ECM in a
small fraction of the latter was likely due to incomplete depletion of
endogenous CD8+ T cells in some mice. This could not be avoided
because the dose of depleting anti-CD8 antibody had to be
sufficient to deplete virtually all endogenous CD8+ T cells while
leaving little antibody to persist until adoptively transfer of PbT-I
cells a week later (otherwise remaining anti-CD8 mAb would have
depleted these PbT-I cells). H&E staining of the brains of mice that
received PbT-I cells showed typical features of CM, such as
haemorrhages and intravascular accumulation of RBC and
leukocytes (Figure S9). These data clearly showed that PbT-I
cells were able to cause ECM.
PbT-I cells cross-react on other species of Plasmodium
As the precise specificity of PbT-I cells was unknown, we
determined whether they recognized other species of Plasmodium.
CFSE-labeled PbT-I cells were adoptively transferred into B6 mice
that were then infected with blood-stage P. chabaudi AS; 6 or 7 days
later proliferation of PbT-I cells was assessed in the spleen
(Figure 5). This showed that PbT-I cells could proliferate in
response to blood-stage P. chabaudi AS. In a similar set of
experiments, PbT-I cells were also shown to respond to blood-
stage infection with P. yoelii XNL (Figure S10). These findings
indicated that PbT-I cells have specificity for multiple Plasmodium
species that cause rodent malaria.
PbT-I cells respond to irradiated PbA sporozoites
While our PbT-I line was generated to blood-stage parasite
infection, a proportion of antigens expressed in the blood stage are
also expressed by sporozoites and during the liver-stage of
infection [23]. To address whether sporozoites could stimulate
PbT-I cells, we adoptively transferred CFSE-labeled PbT-I cells
into B6 mice and then injected them i.v. with radiation-attenuated
PbA sporozoites (RAS). On day 4 post-infection, proliferating
PbT-I cells were detected in the spleen indicating their capacity to
Figure 1. Characterization of T cells from the spleen and lymph
node of PbT-I mice. Cells were harvested from the spleen and the
lymph nodes of PbT-I transgenic or littermate control mice (WT). FACS
analysis was performed to characterize the expression of CD8, CD4 and
the transgenic TCR alpha (Va8.3) and beta (Vb10) chains. (A)
Representative dot-plots showing the proportions of CD8 versus CD4
cells in the spleen and lymph node of PbT-I and WT mice. (B)
Representative histograms showing the expression of the transgenic
TCR Va8.3 and Vb10 chains on the CD8 or CD4 single-positive cells from
the spleen. This experiment was repeated three times with two mice
per experiment.
doi:10.1371/journal.ppat.1004135.g001
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Figure 2. PbT-I cells respond in the spleen to i.v. blood-stage PbA. B6 mice were adoptively transferred with 26106 Ly5.1+ PbT-I cells and the
next day infected i.v. with 106 blood-stage PbA. Spleens were harvested three or five days later and the proliferation of PbT-I cells was analyzed. The
gating strategy to identify PbT-I cells was similar to that shown in Figure S13. (A) Representative histograms showing the proliferation of PbT-I cells
on day three or five post-infection. (B) Number of proliferating PbT-I cells in the spleen and blood of mice infected with PbA for three or five days.
Data are pooled from three experiments. Each data point represents a mouse and the lines represent the mean. Data were compared using student t
test (**, p,0.01; ***, p,0.001). (C) B6 mice were adoptively transferred with 106 CFSE-labeled Ly5.1+ PbT-I cells. The next day, mice were injected i.v.
with 106 blood-stage PbA. Various tissues (spleen, blood, celiac lymph node (ceLN), portal LN (pLN), inguinal LN (iLN), mesenteric LN (mLN)) were
harvested after 2 days and PbT-I cells examined for CD69 and CFSE expression. Profiles are gated on PbT-I cells. This experiment was performed three
times (two-three mice per group) with similar results. Typical profiles are shown. (D) The mean percentage of CD69+ PbT-I cells for the analysis shown
in (C). Histograms represent values from infected animals minus mean values from uninfected animals. Error bars represent standard error of the
mean.
doi:10.1371/journal.ppat.1004135.g002
Cross-Stage Reactive CD8 T Cells in Rodent Malaria
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respond to sporozoites (Figure 6). Additional mice examined on
day 7 did not progress to patency, indicating that day 4 responses
were induced by sporozoites and not by break-through blood-stage
parasites. Eight days after infection, PbT-I cells harvested from the
spleen produced IFNc, TNFa and CD107a (Figure S11),
indicating their development of effector function.
Proliferation of PbT-I cells to i.v. sporozoites occurs
mainly in the spleen and depends on CD8a+ DC
A recent report suggested that the efficiency of intravenous
vaccination with irradiated sporozoites relative to subcutaneous
vaccination may be because the former route allows more
parasites to reach the liver for priming of protective immunity
[19]. To test whether priming by irradiate parasites occurred in
the liver, we injected irradiated sporozoites intravenously and then
1–4 days later examined the activation (CD69 expression)
(Figure 7A, C) and proliferation (Figure 7A, B) of PbT-I cells
in the liver and various lymphoid tissues including the spleen and
lymph nodes. Upregulation of CD69 was seen as early as one day
after infection and was primarily detected in the spleen, with some
expression also seen in the liver draining lymph nodes (celiac LN,
portal LN and the 1st mesenteric LN) [27]. Proliferation closely
followed on day 2, almost entirely in the spleen. These data
suggested that PbT-I cells responded to sporozoites by CD69
upregulation and extensive initial proliferation in the spleen and to
a lesser extent in the liver-draining lymph nodes, but not in the
liver nor other lymph nodes. Divided cells were only evident in the
liver once they were present in the blood and had divided
extensively, suggesting initiation of proliferation elsewhere, most
likely in the spleen.
CD8a+ DC are critical for generating immunity to blood-stage
infection [28,29] and recently the human DC subset equivalent,
BDCA3+ DC, have been implicated in severe malaria in humans
[30,31]. To address whether CD8a+ DC also participated in
responses to sporozoites, we examined proliferation of PbT-I cells
in Batf3-/- mice, which lack this DC subset (Figure 8). The poor
proliferation in Batf3-/- mice compared to wild-type mice revealed
that this response was dependent on CD8a+ dendritic cells.
Cumulative expansion of PbT-I cells responding to liver-
and blood-stage infection
It has been reported that blood-stage infection can impair
immunity to liver-stage antigens [24], though this is disputed by
evidence that there is an equivalent response by liver-stage-specific
transgenic T cells to sporozoites in the presence or absence of a
subsequent blood-stage infection [32]. To resolve this issue with
respect to CD8+ T cell-mediated immunity, we examined the
expansion of PbT-I cells after exposing mice to live sporozoites
(which will infect the liver then generate blood-stage infection), or
irradiated sporozoites alone or followed by blood-stage (iRBC)
infection 2 days later, mimicking the time for blood-stage egress
after live sporozoite infection (Figure 9). Our results clearly
showed that naı¨ve PbT-I cells proliferated to reach greater
numbers if additionally exposed to blood-stage infection, indicat-
ing that T cells with cross-stage specificity can show cumulative
expansion to the liver and bloods stages.
Since sporozoite antigen has been shown to persist in other
models [33], and we could demonstrate some proliferation of PbT-
I cells transferred 2 days but not 7 days after injection of irradiated
Figure 3. PbT-I cells infiltrate the brain and accelerate ECM. B6
mice were adoptively transferred with 26106 or 26104 Ly5.1+ PbT-I cells
or 26106 herpes simplex virus-specific gBT-I cells or left uninjected. The
next day mice were infected i.v. with 106 blood-stage PbA. (A) Mice
were monitored for the development of ECM. Data are pooled from
three independent experiments. The differences between 26106 PbT-I
and the group that did not receive any transgenic cells or the group
that received gBT-I cells are statistically significant (p,0.0001) as
determined by a Log-rank test. (B) Mice were adoptively transferred
with PbT-I cells (filled circle) or gBT-I cells (filled square) or no cells
(open circle) and were sacrificed on days 4, 5 or 6 post-infection. Their
brains were then analysed for the infiltration of PbT-I cells (left) or gBT-I
cells (right). Data are pooled from 2–4 experiments. Data were
compared using student t test (*, p,0.05).
doi:10.1371/journal.ppat.1004135.g003
Figure 4. PbT-I cells induce ECM in mice lacking endogenous
CD8+ T cells. B6 mice were either left undepleted (closed triangles) or
were depleted of endogenous CD8+ T cells (-CD8) seven days before the
adoptive transfer of 26106 naı¨ve PbT-I (filled square) or gBT-I cells (filled
circle) or no cells (open triangles). The next day, mice were infected i.v.
with 106 blood-stage PbA and monitored for the development of
cerebral malaria. Data are pooled from three experiments. The
difference in survival between the following groups was statistically
significant (p,0.0001) as determined by the Log-Rank test: i. B6, -CD8, +
PbT-I and B6, -CD8; ii. B6, -CD8, + PbT-I and B6, -CD8, + gBT-I.
doi:10.1371/journal.ppat.1004135.g004
Cross-Stage Reactive CD8 T Cells in Rodent Malaria
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sporozoites (Figure S12A, B), indicating at least short-term
persistence of the PbT-I antigen, it remained possible that
augmented proliferation of PbT-I cells due to blood-stage infection
might simply relate to additional inflammatory effects, rather than
provision of antigen. To test whether inflammation alone could
boost PbT-I expansion to irradiated sporozoites, 20 nmol of 1668
CpG oligonucleotide (CpG) was used as an inflammatory signal on
day 2 and its effect on expansion of PbT-I cells examined (Figure
S12C). CpG-mediated inflammation failed to induce a significant
increase in PbT-I cell numbers in mice given irradiated
sporozoites two days earlier, suggesting that antigen provided by
blood-stage infection may be important for enhanced prolifera-
tion. This did not, however, formally excluding a role for
inflammatory signals distinct from CpG that are associated with
blood-stage infection.
PbT-I cells protect B6 mice from sporozoite infection
Because only one parasitized hepatocyte needs to survive to
deploy thousands of merozoites into the blood and seed blood-
stage infection, it is very difficult to prevent malaria with
vaccines directed at pre-erythrocytic stages. It follows that any
vaccine targeting pre-erythrocytic stages of infection must
generate sterile immunity to be effective. As the antigen
recognized by PbT-I cells was expressed by sporozoites, we
asked whether this antigen might represent a vaccine candidate
capable of eliciting sterile hepatic immunity. To assess this, we
asked whether PbT-I cells could provide protective immunity
to liver-stage infection. First, we determined an infectious dose
of sporozoites that would lead to just under 100% blood-stage
infection in the absence of PbT-I cells (Figure 10A). From this
we chose 520 sporozoites as our infectious dose. To test the
Figure 5. PbT-I cells respond to P. chabaudi AS. B6 mice were adoptively transferred i.v. with 26106 CFSE-labeled PbT-I cells. The next day, mice
were injected i.v. with 105 P. chabaudi AS. Six or seven days later, spleens were harvested and the proliferation of PbT-I was analyzed. (A)
Representative histograms of CFSE-labeled PbT-I cells in the spleen of uninfected or P. chabaudi infected mice. (B) Number of PbT-I cells in the
spleens of mice on days 6–7. The lines represent the mean and each data point represents a mouse. Data are pooled from three experiments. Data
were compared using student t test (***, p,0.001).
doi:10.1371/journal.ppat.1004135.g005
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protective capacity of PbT-I cells, these cells or control virus-specific
gBT-I cells were activated in vitro and then 76106 cells adoptively
transferred into naı¨ve B6 mice that were subsequently challenged
with 520 live sporozoites (Figure 10B). By monitoring these mice
for blood parasitemia, we showed that PbT-I cells, but not gBT-I
cells, could prevent progression to blood-stage infection, protecting
mice from infection. This indicated that the antigen recognized by
PbT-I cells has the potential to generate sterilizing immunity to
liver-stage infection.
Identification of a candidate antigen recognized by PbT-I
cells
To identify the antigenic determinant recognized by PbT-I
cells, we used an octamer combinatorial peptide library scan
[34] to identify amino acid residues important for PbT-I
activation as measured by MIP1b production (data not
shown). These residues were then used to generate a octamer
motif (x-x-x-(CD)-(WF)-N-x-(LMIV); where x is any amino
acid and residues in brackets are valid for that position) to
search the genomes of the three rodent malaria species for
which PbT-I cells showed reactivity. 151 peptides fitting this
motif were then examined for their capacity to stimulate PbT-I
cells either by CD69 expression or MIP1b production (data
not shown). Six peptide sequences caused some T cell
activation but only one of these (NCYDFNNI (NCY)) was
found to act as a target antigen for endogenous killer T cells
generated in normal B6 mice infected with PbA (Figure 11A
and data not shown). This sequence also induced IFNc
production from endogenous T cells (Figure 11B) and PbT-I
T cells (Figure 11C) responding to blood-stage infection. Note
Figure 6. PbT-I cells proliferate in response to irradiated sporozoites. B6 mice were adoptively transferred with 26106 CFSE-labeled PbT-I
cells. The next day, mice were injected i.v. with 56104–105 radiation attenuated sporozoites (RAS) or equivalent salivary extract. Four days later
spleens were harvested and the proliferation of PbT-I cells was analyzed. (A) Representative histograms showing the proliferation of PbT-I cells in
response to irradiated sporozoites. (B) Pooled data showing the number of divided PbT-I cells from four experiments. The lines represent the mean
and each data point represents a mouse. Mice similarly treated but left until day 7 post-challenge showed no breakthrough in blood-stage infection
indicating full attenuation of sporozoites. Data were compared by one-way ANOVA and Tukey’s multiple comparison test (*, p,0.05).
doi:10.1371/journal.ppat.1004135.g006
Cross-Stage Reactive CD8 T Cells in Rodent Malaria
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that tetramers made with Kb containing NCY were able to
stain PbT-I cells, confirming the Kb-restriction of this
specificity (data not shown). The NCY peptide was derived
from a protein of 745 amino acids (PBANKA_071450), which
is now our leading candidate for the antigen responsible for
priming PbT-I cells.
Discussion
Here we characterize a new TCR transgenic mouse that
produces CD8+ T cells specific for both the blood and liver stages
of rodent malaria. PbT-I cells responded in vivo to the blood-stage
of three different rodent Plasmodium species, PbA, P. yoelii XNL and
P. chabaudi AS. In addition, PbT-I cells responded to mosquito-
derived sporozoites of PbA and were able to provide protection
against sporozoite infection. It remains to be tested as to whether
PbT-I cells also recognize sporozoites from the other rodent
Plasmodium species, but it seems likely that this will be the case
given their blood-stage cross-reactivity. Recognition of blood-stage
parasites as well as mosquito-derived sporozoites, and the ability to
protect against liver-stage infection, suggests that the protein
recognized by PbT-I cells is widely expressed throughout the
parasite life cycle and is potentially well conserved. Identification
of NCYDFNNI as a peptide recognized by PbT-I cells and by
endogenous PbA-induced T cells suggests the protein encoded by
PBANKA_071450, which is of unknown function and undefined
expression pattern, may be the source of the PbT-I epitope.
Construction of parasites deficient in this epitope will be required
for formal proof.
It is notable that while the source protein is encoded in the
genomes of PbA and P. chabaudi, the ortholog appears severely
truncated in P. yoelii and consequently lacks the region containing
Figure 7. PbT-I cells are primed mainly in the spleen when irradiated sporozoites are delivered by the i.v. route. B6 mice were
adoptively transferred with 106 CFSE-labeled PbT-I cells. The next day, mice were injected i.v. with 105 irradiated PbA sporozoites. Various organs
(spleen, blood, liver, different lymph nodes) were harvested on days 1–4 post-vaccination and the activation and proliferation of PbT-I cells was
analyzed by flow cytometry. For gating strategy to identify PbT-I cells see Figure S13. (A) Representative histograms showing the proliferation of
PbT-I cells versus the upregulation of CD69 in the various organs. (B) Number of divided PbT-I cells in the different organs. The insert shows a more
sensitive scale to identify the few divided PbT-I cells in the liver and lymph nodes on days three and four post-infection. (C) Percentage of CD69+ PbT-
I cells in each organ on days 1-2. Error bars represent standard error of the mean. Data are pooled from three independent experiments.
doi:10.1371/journal.ppat.1004135.g007
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NCYDFNNI found in other species. As PbT-1 cells were able to
respond to P. yoelii, the authentic antigen must be present in this
species. Whether this invalidates the gene product of
PBANKA_071450 as the authentic PbT-I antigen, or is explained
by sequencing error within the P. yoelii genome, or has some other
basis remains to be established. Whatever the case, the
NCYDFNNI epitope is clearly recognized by PbT-I cells and
can be used to stimulate these transgenic T cells as well as
endogenous T cells specific for PbA.
Evidence that immunization with live blood-stage parasites
can protect against the liver-stage infection [25], suggests that
multi-stage antigens like that recognized by PbT-I cells can be
protective. Our study extends this concept by indicating that
CD8+ T cells of a single specificity for a blood-stage antigen can
protect against liver-stage infection when the antigen is also
expressed during the liver stage. It has been reported that blood-
stage infection can impair immunity to liver-stage antigens [24],
though this is disputed by the above study, which uses blood-stage
infection to induce anti-sporozoite immunity [25] and by another
study that shows an equivalent response by liver-stage-specific
transgenic T cells to sporozoites in the presence or absence of a
subsequent blood-stage infection [32]. The availability of PbT-I
cells will give us the opportunity to examine this relationship when
the relevant antigen is expressed during both blood- and liver-
stages and to determine how antigens presented during the blood-
stage might influence the effector function of T cells capable of
recognizing liver-stage antigens. Clearly, in our experiments,
exposure of cells primed to liver-stage parasites did not impair
their capacity to respond to blood-stage parasites, but increased
the expansion of PbT-I cells. This raises the possibility that CD8+
T cells specific for antigens expressed in both stages of infection
may have a selective advantage for expansion over single stage
specific T cells.
The broad cross-reactivity of this TCR transgenic line means
that it is suited to exploring the role of CD8+ T cells in several
rodent malaria models. For blood-stage infection, this is most
relevant to PbA, where ECM is dependent on CD8+ T cells.
However, CD8+ T cells have been implicated in protective
immunity to blood-stage infection by P. yoelii 17XL [35], raising
the possibility that this protective process could be explored using
Figure 8. CD8a+ DC are required for presentation of irradiated sporozoites delivered by the i.v. route. B6 or Batf3-/- mice were
adoptively transferred with 106 CellTracker Violet-labeled PbT-I cells then infected with irradiated PbA sporozoites. (A) Representative histograms
show the proliferation of PbT-I cells in B6 and Batf3-/- mice on day 5 after injection with irradiated sporozoites. (B) Pooled data showing the
proliferation of PbT-I cells from three experiments. The lines represent the mean and each data point represents a mouse. Data were compared by
one-way ANOVA and Tukey’s multiple comparison test (***, p,0.001).
doi:10.1371/journal.ppat.1004135.g008
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PbT-I cells. These transgenic T cells should also be highly relevant
for analysis of liver-stage immunity, as CD8+ T cells are critical for
protection at this stage of infection [15,36]. Here we used PbT-I
cells to investigate the site of priming and T cell expansion after
intravenous administration of irradiated sporozoites. This study
was prompted by the implication that the effectiveness of this route
of immunization was related to its capacity to prime in the liver
[19]. Our analysis revealed that T cells showed signs of activation
in the spleen and in the liver draining lymph nodes, but not in the
liver itself, and subsequent examination of T cell proliferation
showed that most PbT-I T cell proliferation occurred in the
spleen. While our study does not exclude a role for the liver in
tailoring the response, it suggests that at least the initial priming
steps are unlikely to occur in this site. Thus, efficient priming via
this route most likely derives from the large load of irradiated
sporozoites deposited in the spleen after intravenous administra-
tion and the high frequency of T cells found in this organ. This
contrasts infection by mosquito bite, which favors priming within
skin draining lymph nodes [13], probably as a consequence of
local deposition of sporozoites within the dermis of the skin. Our
findings suggest that the spleen is the main site for priming
sporozoite specific T cells after intravenous administration of
parasites, but they do not formally exclude the liver draining
lymph nodes or the liver as important sites of activation for
protective immunity.
Initiation of PbT-I proliferation in the spleen in response to
intravenous injection of irradiated PbA sporozoites also demon-
strated that the sporozoites themselves expressed the antigen
recognized by PbT-I cells and that conversion to later liver stages
of development was not necessary to provide antigen capable of
stimulating these T cells. Furthermore, it showed that the same
DC subset as required for priming CD8+ T cell immunity to
blood-stage infection, i.e the CD8a+ DC [28,29], was responsible
for inducing CD8+ T cell responses to the liver-stage parasites.
Extraction of putative CD8a+ DC from the liver 6 days after
sporozoite infection also suggested that these DC might contribute
to antigen presentation in the liver at late time points after
infection [37], though this idea should be taken with caution as
CD8 T cells can express CD11c when activated and can be easily
mistaken for DC. This common use of CD8a+ DC probably
Figure 9. PbT-I cells proliferate to greater numbers when
sequentially primed with liver-stage then blood-stage PbA
parasites. B6 mice were adoptively transferred with 56104 GFP-
expressing PbT-I cells then on day 0 they were injected with 56104 live
sporozoites alone, or 56104 radiation-attenuated sporozoites alone
(RAS), or RAS followed 2 days later by 104 iRBC (RAS + iRBC), or nothing
followed 2 days later by 104 iRBC (iRBC) or left uninfected (naı¨ve). On
day 7 spleens were harvested and the number of PbT-I cells
enumerated. Data are pooled from four experiments. At the time of
sacrifice, blood parasitemias were equivalent in the two groups of mice
given iRBC (RAS + iRBC = 5.661.8; iRBC alone = 5.160.7). Data were
compared by one-way ANOVA and Tukey’s multiple comparison test
(n.s., non-significant; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.ppat.1004135.g009
Figure 10. Activated PbT-I cells confer protection against a
sporozoite challenge. (A) B6 mice were infected i.v. with 300 (n = 25),
520 (n = 22) or 900 (n = 15) PbA sporozoites and the % of mice that
developed a blood-stage infection (black bars) by day 14 is shown. Data
are pooled from three to five experiments. Data were analyzed using
Fisher’s exact test with no significant difference between groups (p.
0.05). (B) B6 mice were adoptively transferred with 76106 in vitro
activated PbT-I cells (n = 20) or activated virus-specific gBT-I cells (n = 16)
or Nil (n = 17). Two hours later, mice were infected i.v. with 520
sporozoites. Blood-stage parasitemia was monitored to day 14 post-
infection. Shown is the percentage of mice that develop a blood-stage
infection (black bars) by day 14. Data are pooled from three
experiments. Data were analyzed using Fisher’s exact test with the
PbT-I treated group significantly different from the other two groups
(p,0.0001) and no significant difference between these two groups
(p.0.05).
doi:10.1371/journal.ppat.1004135.g010
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reflects their dominant capacity to cross-present antigens [38]. The
ability of PbT-I cells to protect against infection by PbA
sporozoites is encouraging because sterilizing immunity requires
destruction of all infected hepatocytes. Our experiments used
76106 activated PbT-I cells to demonstrate protection, which is a
relatively high number of cells but certainly achievable by
vaccination. Identification of the antigen recognized by this
TCR transgenic line should allow development of vaccination
strategies to test the protective power of this potentially conserved
antigen expressed in multiple stages of the life cycle. This
approach has the potential to be highly effective since both stages
of infection are shown to boost responses by CD8+ T cells with
such multi-stage specificity. One concern with this type of multi-
stage antigen, however, is that priming of T cells by sporozoites
may enhance the potential for development of ECM mediated by
the same cells during the blood-stage of the infection. While
directly relevant for PbA infection where ECM is commonplace,
this might not be of relevance to infection models where ECM is
not seen e.g. P. yoelii XNL infection. Given the strongly argued
lack of adaptive immune involvement in human cerebral malaria,
this concern may also be irrelevant for human vaccination
approaches. However, caution should be adopted here since our
understanding of pathology in human cerebral malaria is still
somewhat limited.
In conclusion, the PbT-I TCR transgenic line represents a
versatile tool for studying CD8+ T cell immunity to a multitude of
rodent Plasmodium species during both the liver- and blood-stages
of infection. The current study highlights the spleen as a major
organ of priming for intravenously-introduced blood- or liver-stage
parasites and suggests that T cells with specificity for antigens
expressed in both stages may contribute to pathology or
protection, depending on the stage of life cycle.
Methods
Ethics statement
All procedures were performed in strict accordance with the
recommendations of the Australian code of practice for the care
and use of animals for scientific purposes. The protocols were
approved by the Melbourne Health Research Animal Ethics
Committee, University of Melbourne (ethic project IDs: 0810527,
0811055, 1112347, 0911527).
Mice, mosquitos and parasites
C57BL/6 (B6) mice, B6.Ly5.1 mice, MHC I-/- mice, Kb-/-
mice, Batf3-/- mice and the transgenic strains gBT-I [39] and
PbT-I were used between 6-12 weeks and were bred and
Figure 11. Identification of a peptide antigen (NCYDFNNI)
recognized by endogenous T cells and PbT-I cells from PbA-
infected mice. (A) B6 mice were infected with 106 blood-stage PbA
then cured by treatment with chloroquine from days 4 to 6. On day 7
mice were adoptively transferred with peptide-labeled target cells and a
day later spleens were recovered and examined for target cell killing.
Data are from two experiments, each of which used a test peptide,
NCYDFNNI, and control peptides (NNFDFNNL or NIYDFNFI; pooled). (B,
C) IFNc production by T cells responding to PbA. B6 mice were either
left untreated (B) or were adoptively transferred with 56104 PbT-I cells
(C). All mice were then infected with 106 blood-stage PbA and cured of
infection by chloroquine treatment from days 4 to 6. On day 7, spleens
were removed and an intracellular cytokine assay performed to detect
IFNc expression by endogenous CD8 T cells (B) or PbT-I cells (C). Data
are from two experiments, each of which used a test peptide,
NCYDFNNI, and a control peptide (SIINFEKL; OVA). Data were compared
using student t test (***, p,0.001; ****, p,0.0001).
doi:10.1371/journal.ppat.1004135.g011
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maintained at the Department of Microbiology and Immunol-
ogy, The University of Melbourne. Batf3-/- mice used in this
study had been backcrossed 10 generations to B6. Animals
used for the generation of the sporozoites were 4–5 week old
male Swiss Webster mice were purchased from the Monash
Animal Services (Melbourne, Victoria, Australia) and main-
tained at the School of Botany, The University of Melbourne,
Australia.
Anopheles stephensi mosquitoes (strain STE2/MRA-128 from The
Malaria Research and Reference Reagent Resource Center) were
reared and infected with PbA as described [40]. Sporozoites were
dissected from mosquito salivary glands [41], resuspended in cold
PBS, irradiated with 20,000 rads using a gamma 60Co source, and
administered to mice i.v. The rodent malaria lines PbA clone
15cy1, P. chabaudi AS and P. yoelii XNL were used in this study.
Generation of transgenic PbT-I
Transgenic PbT-I mice were generated using the V(D)J
segments of the TCRa- and b-genes of a CD8+ T cell hybridoma
(termed B4) specific for an unidentified blood-stage PbA antigen.
This hybridoma was derived from T cells extracted from the
spleen of a B6 mouse at day 7 after infection with PbA. 36106
splenocytes from a mouse previously infected with PbA were co-
cultured with 56105 conventional DC (extracted from the spleen
of FMS-like tyrosine kinase 3 receptor ligand (Flt3-L) treated B6
mice) that were pre-loaded for 2 hours with 26106 PbA schizont
lysate as previously described [42] in complete RPMI at 6.5%
CO2, 37uC. One week later, cultured cells were re-stimulated for a
week with fresh DC and PbA schizont lysate. To generate PbA-
specific hybridomas, in vitro cultured cells were then fused with the
BWZ36.GFP fusion partner and exposed to drug selection [43].
This led to isolation of the Kb-restricted B4 hybridoma (Figure S1)
from which PbT-I T cell receptor genes were derived.
TCR Va usage was defined using 59 RACE PCR on cDNA
converted from the RNA of the B4 hybridoma. Sequencing
analysis revealed that the TCR a-chain consisted of AV8S6 and
Ja17 and Ca2 gene segments. The TCR a region was amplified by
PCR from the cDNA of the B4 hybridoma using the forward
primer GGATCCAGTGTCATTTCTTCCCT containing a
BamHI recognition sequence at the 59 end, designed to bind the
59 UTR region of AV8S6, and the reverse primer CAGATCT-
CAACTGGACCACAG containing a BglII recognition sequence
at the 59 end, specific for the Ca region. The AV8S6-Ja17-Ca2
segment was cloned into the BamHI site of the pES4 cDNA
expression vector, comprising the Ig-H chain enhancer, the H2-Kb
promoter and the polyadenylation signal sequence of the human
b-globulin gene [44]. To prepare the a-chain transgenic construct
for microinjection, the pES4-VJC construct was digested with the
restriction enzymes ClaI and NotI, and the digested mix was
subjected to agarose gel electrophoresis. The ,5.6 kb transgenic
insert containing the VJC sequence, the promoter and enhancer
sequences was excised from the gel, purified and quantitated for
microinjection.
TCR Vb usage was defined by PCR on cDNA converted from
the RNA of the B4 hybridoma using the forward primer
CCTGCCTCGAGCCAACTATGGG specific for the Vb10 gene
and the reverse primer CCAGAAGGTAGCAGAGACCC spe-
cific for the Cb gene. Sequencing analysis revealed that the TCR
b-chain consisted of Vb10 (BV10S1A1), Db2 and Jb2.2. The
TCR b-chain was amplified by PCR from the genomic DNA of
the B4 hybridoma using the forward primer GATCGATGTCC-
TAGGCCAGGAGATATGA specific for the Vb10, incorporat-
ing a ClaI restriction enzyme site at the 59 end, and the reverse
primer GATCGATAAGCTCAGTCCAAGA specific for Jb2.2
and incorporating a ClaI site at the 59end. The Vb10 (BV10S1A1),
Db2 and Jb2.2 segment was cloned into the ClaI site of the
p3A9CbTCR gDNA expression vector, comprising the TCR b-
chain enhancer, the 2B4-derived 59 region and leader sequence
and the B3-derived promoter and coding regions [45]. To prepare
the construct for microinjection, the p3A9CbTCR VDJ construct
was digested with the restriction enzymes ApaI and NotI, and the
digested mix was subjected to agarose gel electrophoresis. The
larger fragment (,11 kb) transgenic insert containing the VDJ
sequence, Cb sequence and the promoter and enhancer sequences
was excised from the gel, purified and quantitated for microin-
jection.
Flow cytometry
Cells were labeled with monoclonal antibodies specific for CD8
(53-6.7), CD4 (RM 4-5), Thy1.2 (30-H12), CD45.1 (A20), Va8.3
(B21.14), Vb10 (B21.5) or CD69 (H1.2F3). Dead cells were
excluded by propidium iodide staining. Cells were analyzed by
flow cytometry on a FACsCanto or Fortessa (BD Biosciences),
using the Flowjo software (Tree Star Inc.).
Infection of mice and chloroquine treatment
Unless otherwise stated, mice were infected i.v. with 106 PbA
infected RBC (iRBC) in 0.2 ml of Hank’s balanced salt solution
(HBSS). In some experiments, mice were infected i.v. with 105
P.chabaudi iRBC or i.v. with 104 P. yoelii iRBC or with 300, 520,
900, 56104 or 105 PbA sporozoites as stated in the figure legends.
Mice infected with 104 PbA infected RBC were injected i.p. with
0.4 mg chloroquine dissolved in water on days 6 and 7, before
being euthanized for analysis on day 8 post-infection.
T cell isolation and adoptive transfer
CD8+ T cells were negatively enriched from the spleens and
lymph nodes of transgenic mice and labelled with CFSE as
described [46]. Purified cells were injected i.v. in 0.2 ml HBSS. To
deplete endogenous CD8+ T cells before adoptive transfer, B6
mice were injected i.p. with 100 mg of anti-CD8 antibody (clone
2.43) 7 days prior to the transfer of PbT-I or gBT-I cells.
In vivo proliferation assay
1–26106 CFSE-labelled Ly5.1+ PbT-I cells were adoptively
transferred into Ly5.2+ B6 mice a day before mice were infected
with blood-stage PbA, P. chabaudi, or P. yoelii or with PbA
sporozoites. In other experiments, 56104 or 16106 uGFP PbT-I
cells labelled with CellTracker Violet stain (Invitrogen) were
adoptively transferred into Ly5.2+ B6 or Batf3-/- mice a day before
infection with irradiated sporozoites, or 3 days before infection
with PbA iRBC. Spleens and other organs were harvested on
various days post-infection for the analysis of PbT-I proliferation
by flow cytometry.
Dendritic cell isolation
Dendritic cells were purified from the spleens of mice as
previously described (28). Briefly, spleens were finely minced and
digested in 1 mg/ml collagenase 3 (Worthington) and 20 mg/ml
DNAse I (Roche) for 20 min at room temperature. After removing
undigested fragments by filtering through a 70 mm mesh, cells
were resuspended in 5 ml 1.077 g/cm3 nycodenz medium
(Nycomed Pharma AS, Oslo, Norway), layered over 5 ml
nycodenz medium and centrifuged at 17006g at 4uC for
12 min. The light density fraction was collected and DC were
negatively enriched by incubation with a cocktail of rat
monoclonal anti-CD3 (clone KT3-1.1), anti-Thy-1 (clone T24/
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31.7), anti-Gr1 (clone RB68C5), anti-CD45R (clone RA36B2) and
anti-erythrocyte (clone TER119) antibodies followed by immuno-
magnetic bead depletion using BioMag goat anti-rat IgG beads
(Qiagen).
Functional assay with hybridomas and IL-2 ELISA
56104 DC extracted from the spleens of naive WT, MHC-I-
deficient or Kb-deficient mice and resuspended in complete
DMEM medium supplemented with 10% foetal calf serum (FCS)
were cultured for 1 h with titrated amounts of lysed whole blood
containing mixed stages of PbA parasites before adding 56104 B4
hybridoma cells. After culture for 40 h at 37uC in 6.5% CO2
supernatants were collected and concentrations of IL-2 were
assessed using the Mouse IL-2 ELISA Ready-Set-Go kit
(eBiosciences) following manufacturer’s instructions.
In vitro antigen presentation assay
PbA mixed blood-stages and schizont enriched parasite lysate
were prepared as previously described [42]. Conventional DC
isolated from the spleen of FMS-like tyrosine kinase 3 receptor
ligand (Flt3-L) treated Ly5.2+ B6 mice [42] were incubated with
titrated amounts of lysate from either the mixed blood-stages or
the schizont-enriched parasites for 2 hours before the addition of
CFSE-labeled Ly5.1+ PbT-I cells. After 60 hours of incubation at
6.5% CO2, 37uC, cells were harvested for analysis by flow
cytometry.
Ex vivo intracellular cytokine staining (ICS) assay
To detect degranulation and the production of cytokines
IFNc and TNFa from antigen specific cells, splenocytes from
mice (either normal B6 mice or those adoptively transferred
with PbT-I) infected for 7 days with irradiated sporozoites or
7–8 days with blood-stage PbA were restimulated by 5 mg/ml
plate-bound anti-CD3 or 1 mg/ml peptide for 5 hours at 37uC
in the presence of 10 mg/ml brefeldin A, monensin and anti-
CD107 antibody (clone eBio1D4B). Cells were then surface
labeled with antibodies and intracellular cytokine staining was
performed to detect intracellular IFNc and TNFa using
Cytofix/Cytoperm Fixation and Permeabilization Solution
(BD) according to the manufacturer’s instructions. Results
were represented in Venn diagrams using the online tool at
www.venndiagram.tk.
Generation of in vitro activated CTL
PbT-I or gBT-I isolated from the spleen and lymph nodes
were stimulated with media containing 10% FCS, 10 U/ml IL-
2 and 5 mg/ml anti-CD28 in 75 cm2 tissue culture flasks pre-
coated with 10 mg/ml anti-CD3 (clone 2c11), anti-CD8 (clone
53-6.7) and anti-CD11a (clone 121/7.7). 40 hours later, cell
cultures were divided into two equal volumes and given an
equivalent volume of fresh medium before culturing for
24 hours. Cells were then harvested and centrifuged over
lymphocyte separation media to remove dead cells. In vitro
activated cells generated using this method were routinely
.90% pure.
Isolation of cells from the brain
Mice were perfused intracardially with 10 ml PBS prior to
harvesting of the brain. Brains were cut into fine fragments,
washed once with media and digested with collagenase/DNAse
(1 mg/ml collagenase III (Roche); 20 mg/ml DNAse I,
(Worthington) for 1 hour at room temperature with rotation.
Samples were filtered through 75 mm nylon mesh to remove
undigested fragments and then centrifuged once at 596 g, 5
minutes at 4uC. The pellet was resuspended in 7 ml 33%
Percoll diluted in media, and centrifuged at 400 g for 20
minutes at room temperature with low brake. The supernatant
was discarded and the pellet containing RBC was incubated
with 500 ml RBC lysis buffer for 2 minutes on ice. Cells were
washed twice with FACS buffer followed by surface staining
with various antibodies.
Generation and monitoring of ECM
Mice infected with blood-stage PbA were monitored daily for
the development of ECM. Mice were considered to have ECM
when showing signs of neurological symptoms such as ataxia and
paralysis, evaluated as the inability of mice to self-right.
Hematoxilin and eosin (H&E) staining of brain sections
Brains were fixed in 4% paraformaldehyde followed by 70%
ethanol overnight and then stained by H&E.
Combinatorial peptide library scan
An octamer combinatorial peptide library in positional scanning
format [34] was synthesized (Pepscan Presto, Netherlands). For
combinatorial peptide library screening, splenocytes from trans-
genic PbT-I mice were purified, washed and rested overnight in
RPMI 1640 containing 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 2 mM L-glutamine and 2% heat inactivated fetal calf
serum (all Life Technologies). In 96-well U-bottom plates, 66104
splenocytes target cells were incubated with 160 library mixtures
(at 100 mM) in duplicate for two hours at 37uC. Following peptide
pulsing, 36104 PbT-I splenocytes were added and the assay was
incubated overnight at 37uC. The supernatant was then harvested
and assayed for MIP-1b by ELISA according to the manufactur-
er’s instructions (R&D Systems).
Assessment of peptide stimulation of PbT-I cells by CD69
expression
56105 GFP-expressing PbT-I lymph node and spleen cells
together with 105 B6 spleen cells and peptide (titrated in 10-fold
steps from 5–5000 pM) were pelleted together in a 96-well U-
bottom plate and incubated for 3 hours at 37uC (6.5% CO2). Cells
were then stained with antibodies specific for CD8 and CD69 and
the proportion of CD69+CD8+GFP+ cells determined.
In vivo CTL assay for lytic activity
To detect peptide-specific lytic activity in vivo, mice were
infected for 7 days with 106 blood-stage PbA and cured by
chloroquine treatment from day 4–6 before adoptive transfer of
target cell populations. In vivo cytotoxicity was performed
essentially as described [42], with the modification that target
cells were a mixture of CFSElo B6 spleen cells, DsRed-expressing
splenocytes and GFP-expressing splenocytes, the latter two
populations coated with test peptides at 1 mg/ml. Equal numbers
of cells were combined and 2.46107 cells were injected into host
mice and 18 h later spleen cells were harvest for flow cytometric
assessment of lysis 18 h later within the spleen.
Supporting Information
Figure S1 Kb restricted recognition by the B4 hybrid-
oma specific for PbA. Dendritic cells were enriched from the
spleens of naive B6 (filled circle), MHC-I-deficient (filled triagle),
or Kb-deficient (open diamond) mice and cultured for 1 h with
titrated amounts of lysed blood-stage PbA. B4 hybridoma cells
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(from which the PbT-I TCR genes were isolated) were then added
to the cultures for 40 h before measuring IL-2 in the supernatant
by ELISA. Data points denote mean of IL-2 concentration and
error bars represent SEM. Data were pooled from 2 independent
experiments.
(PDF)
Figure S2 Characterization of T cells from the lymph
node of PbT-I mice. Cells were harvested from the lymph nodes
of PbT-I transgenic or littermate control B6 mice (WT). FACS
analysis was performed to characterize the expression of CD8, CD4
and the transgenic TCR alpha (Va8.3) and beta (Vb10) chains.
Representative histograms show the expression of the transgenic
TCR Va8.3 and Vb10 chains on the CD8 (upper) and CD4 (lower)
single-positive cells from the LN. This experiment was repeated
three times with two mice per experiment.
(PDF)
Figure S3 Enumeration of T cells in the spleen, lymph
nodes and thymus of PbT-I mice. Cells were harvested from
the spleen, lymph nodes or thymus of PbT-I transgenic or
littermate control wild-type (WT) mice. (A) The total number of
live cells and (B) the proportion of T cells expressing either CD4 or
CD8 for the spleen and lymph nodes or CD4 or CD8 or double
positive (DP) for the thymus. This experiment was repeated three
times with two mice per experiment.
(PDF)
Figure S4 Characterization of cells in the thymus of
PbT-I mice. (A) Representative dot-plots showing CD4 and CD8
expression in the thymus of PbT-I mice or littermate WT controls.
(B) Representative histograms showing the expression of the
transgenic TCR Va8.3 and Vb10 chains on the single positive
CD8 or CD4, double positive (DP) and double negative (DN)
thymocytes. This experiment was repeated three times with two
mice per experiment.
(PDF)
Figure S5 PbT-I is specific for blood-stage PbA. (A) 105
CFSE labeled PbT-I cells were incubated with 26105 dendritic cells
that were pre-incubated with titrated amounts of PbA lysate from
either schizonts-enriched (filled circle) or mixed blood-stage parasites
(open circle). 60 hours later, the proliferation of PbT-I cells was
assessed by flow cytometry. Data are pooled from two experiments.
(PDF)
Figure S6 PbT-I T cells do not respond to herpes
simplex virus type 1 infection. B6 mice were adoptively
transferred with 106 Ly5.1 gBT-I cells together with 106 GFP-
expressing PbT-I cells, each population labeled with Cell-Tracker
Violet. The next day, mice were infected i.v. with 104 blood-stage
PbA or 106 pfu HSV-1 or were left uninfected (Naı¨ve). Spleens
were harvested five days later and the proliferation of PbT-I and
gBT-I cells was analyzed. (A) Representative histograms showing
the proliferation of PbT-I cells and gBT-I cells in naı¨ve mice or on
day five post-infection. Note that PbT-I cells have a natural higher
level of homeostatic proliferation than gBT-I cells, as shown in
naı¨ve hosts. (B) Number of PbT-I cells (left) or gBT-I cells (right) in
the spleen of naı¨ve mice or those infected with either blood-stage
PbA or HSV-1 for five days. Data shown from one of two
representative experiments.
(PDF)
Figure S7 PbT-I cells primed during a blood-stage PbA
infection are functionally competent. B6 mice were
adoptively transferred with 56104 GFP-expressing PbT-I cells
and the next day infected i.v. with 104 blood-stage PbA. Infected
mice were injected i.p. with 0.4 mg chloroquine on days 6 and 7 to
cure of parasitemia. Eight days after infection, spleens were
harvested and intracellular cytokine staining was performed to
assess degranulation (CD107a) and cytokine production (IFNc and
TNFa) by PbT-I cells. (A) Bar graph showing the mean percentage
of PbT-I cells expressing CD107a, IFNc or TNFa. Error bars
represent standard error of the mean. Data are pooled from two
experiments with two mice per experiment. (B) Venn diagram
depicting the co-expression of cytokines and CD107a by PbT-I
cells from a representative mouse.
(PDF)
Figure S8 Accumulation of CD8+ T cells in the brains of
mice given PbT-I cells and infected with blood-stage
PbA. Mice adoptively transferred with PbT-I cells (filled circle) or
gBT-I cells (filled square) or no cells (open circle) were sacrificed on
days 4, 5 or 6 post-infection with blood-stage PbA and their brains
were analyzed for the infiltration of CD8+ T cells. Total number of
CD8+ T cells sequestered in the brains of mice at the times shown.
Data are pooled from 2-4 experiments. Data were compared using
student t test (*, p,0.05).
(PDF)
Figure S9 PbT-I cells induced ECM after PbA infection.
Hematoxilin and eosin staining of sagittal sections of the brains of
PbA-infected C57BL/6 mice. Mice were divided into three cohorts
and either left untreated (A–C), depleted of endogenous CD8 T cells
(D–F), or transferred with 26106 naı¨ve PbT-I cells 7 days after
endogenous CD8 T cell depletion (G–I). One day after PbT-I
transfer mice were infected with 106 blood-stage PbA. On day 6
after infection, untreated and PbT-I transferred mice developed
ECM. All mice were then killed and their brains removed for
histological examination. Typical leukocyte and RBC aggregates
could be found in the brain vessels (A, G) and meninges surrounding
cerebellar folia (C, I) of ECM-developing mice. These were absent
from ECM-resistant mice (D, F). The olfactory bulbs of mice with
ECM showed widespread haemorrhages (B, H), in contrast with
their ECM-resistant counterparts (E). Size bars: 50 mm.
(PDF)
Figure S10 PbT-I cells cross-react with P. yoelii XNL. B6
mice were adoptively transferred i.v. with 56105 CFSE-labeled
PbT-I. The next day, mice were injected i.p. with 105 P. yoelii XNL.
Six days later, spleens were harvested and the proliferation of PbT-I
was analyzed. The lines represent the mean and each data point
represents a mouse. Data are from one representative experiment of
two. Data were compared using student t test (**, p,0.01).
(PDF)
Figure S11 B6 mice were adoptively transferred with
56104 GFP-expressing PbT-I and the next day infected
i.v. with 105 irradiated sporozoites. Eight days later, spleens
were harvested and intracellular cytokine staining was performed to
assess degranulation (CD107a) and cytokine production (IFNc and
TNFa) by PbT-I cells. (A) Percentage of PbT-I cells expressing
CD107a, IFNc or TNFa. Error bars represent standard error of the
mean. Data are pooled from two experiments with four mice per
group. (B) Venn diagram depicting the co-expression of cytokines
and CD107a by PbT-I cells from a representative mouse.
(PDF)
Figure S12 The effect of inflammation on expansion of
PbT-I cells to irradiated sporozoites. (A) PbT-I T cells
proliferate to sporozoite antigen when introduced 2 days but not 7
days after injection of irradiated sporozoites. B6 mice were
untreated (naı¨ve, grey lines) or injected with 56104 irradiated
sporozoites (RAS, black lines) on day 0 and then 0, 2 or 7 days
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later were transferred with 2.56105 CellTracker Violet-labeled
GFP-expressing PbT-I cells. On day 7 after PbT-I cell transfer,
spleens were harvested and the proliferation profile of PbT-I cells
examined. Data are representative of 1-3 experiments. (B) Number
of PbT-I cells recovered from mice shown in (A). Closed symbols
are from 1-3 experiments with 2.56105 transferred PbT-I cells.
Open symbols are from 2 experiments with 5.06104 transferred
PbT-I cells. Each time point represents at least 3 experiments. Data
were log10 transformed and compared by one-way ANOVA and
Tukey’s multiple comparison test. (***, p,0.001, n.s. p.0.05). (C)
CpG oligonucleotide induced inflammation did not enhance
expansion of PbT-I cells. B6 mice were adoptively transferred with
5 x 104 GFP-expressing PbT-I cells and left uninfected (naı¨ve) or
infected with 56104 irradiated sporozoites (RAS). Two days later,
mice were left untreated or injected with 20 nmol of 1668 CpG
oligonucleotide (+CpG). On day 7 spleens were harvested and PbT-
I cells enumerated. Data are pooled from two experiments. Data
were compared by one-way ANOVA and Tukey’s multiple
comparison test. There were no significant differences between
similar groups treated with or without CpG (p.0.05).
(PDF)
Figure S13 To identify Ly5.1+ PbT-I cells by flow
cytometry after adoptive transfer into B6 mice, cells
from tissues of recipient mice were gated sequentially as
shown in graphs A–E. PbT-I cells were identified as
Ly5.1+, Va8.3+ CD8+ cells.
(PDF)
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